Literature DB >> 11474485

Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth.

M Igarashi1, A Hirata, H Yamaguchi, H Tsuchiya, H Ohnuma, M Tominaga, M Daimon, T Kato.   

Abstract

This study investigates whether pioglitazone could suppress an atherogenic process such as balloon-injured carotid intimal thickening and the proliferation of vascular smooth muscle cells (VSMC). We first examined the effect of pioglitazone to determine whether it could suppress intimal thickening induced by balloon catheterization in Sprague-Dawley rats. After 14 days postcatheterization in the left common carotid artery, the neointimal layers were completely occupied by proliferated VSMC, and the area ratio of neointima to media treated with 10 mg/kg/d of pioglitazone was significantly decreased to 57%. Next, we evaluated the effect of pioglitazone on the proliferation of rat cultured VSMC. Piogliotazone dose-dependently decreased the values of DNA synthesis, total cellular protein content, phosphorylations of extracellular signal-regulated protein kinase 1/2 and mitogen-activated protein kinase kinase 1/2, and proliferative cell nuclear antigen in VSMC. Pioglitazone also inhibited the phosphorylation of Pyk2. We conclude that pioglitazone itself could be effective for suppressing the growth of VSMC and consequent carotid intimal thickening. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474485     DOI: 10.1053/meta.2001.24869

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Pioglitazone Attenuates Injury-Induced Neointima Formation in Mouse Femoral Artery Partially through the Activation of AMP-Activated Protein Kinase.

Authors:  Islam Osman; Arwa Fairaq; Lakshman Segar
Journal:  Pharmacology       Date:  2017-05-09       Impact factor: 2.547

Review 2.  Are thiazolidinediones good or bad for the heart?

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

3.  PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms.

Authors:  Jane E Ward; Haslinda Gould; Trudi Harris; John V Bonacci; Alastair G Stewart
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

4.  Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.

Authors:  Islam Osman; Lakshman Segar
Journal:  Biochem Pharmacol       Date:  2015-11-28       Impact factor: 5.858

5.  Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance.

Authors:  Jin Yokoyama; Naoyuki Sutoh; Takumi Higuma; Daisuke Horiuchi; Chisato Katoh; Takashi Yokota; Takashi Echizen; Shingo Sasaki; Hiroyuki Hanada; Tomohiro Osanai; Ken Okumura
Journal:  Heart Vessels       Date:  2007-05-21       Impact factor: 2.037

6.  Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Xinbin Zhou; Shenjie Chen; Min Zhu; Junyi Hua; Jin Dai; Xiaoming Xu; Yuangang Qiu; Wei Mao
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

7.  Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation.

Authors:  Hye Won Lee; Han Cheol Lee; Bo Won Kim; Mi Jin Yang; Jin Sup Park; Jun Hyok Oh; Jung Hyun Choi; Kwang Soo Cha; Taek Jong Hong; Sang-Pil Kim; Seunghwan Song; Jong-Ha Park
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

8.  Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions.

Authors:  Karen L Walker; Daniel B Walsh; Philip P Goodney; Samantha A Connell; David H Stone; Richard J Powell; Eva M Rzucidlo
Journal:  BMC Cardiovasc Disord       Date:  2014-12-11       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.